Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making

Completed

Conditions studied: Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease, CAD, CVD, CHD

In brief

The purpose of this study is to understand the use of Corus CAD also known as Age/Sex/Gene Expression score (ASGES) in the clinical decision making process of patients who underwent the evaluation of chest pain or anginal equivalent symptoms. Specifically, to better understand whether the use of the assay in clinical decision making resulted in changes in noninvasive diagnostic test ordering or diagnostic yield of additional tests ordered and/or invasive angiography.

Key facts

Study ID

NCT02223286

Run by

CardioDx

People needed

552

Starts

2013-03-01

Expected to finish

2014-08-01

Last updated by the study team

2018-02-22

Who can join

Age: 21 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Symptoms suggestive of CAD, according to the opinion of the site clinician
• Age >= 21 years

You may not qualify if…

• History of myocardial infarction (MI)
• History of high risk unstable angina, systemic infections or systemic inflammatory conditions
• Current MI or acute coronary syndrome
• Current New York Heart Association (NYHA) class III or IV congestive heart failure symptoms
• Known/documented CAD
• History/current Diabetes Mellitus
• Taking steroids, immunosuppressive agents, or chemotherapeutic agents, at time of chest pain presentation

Where it is running

• John C. Lincoln Heart Institute — Phoenix, Arizona, United States
• Piedmont Heart Institute — Blue Ridge, Georgia, United States
• Heart Associates — Youngstown, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.